← All stories
Markets
GSK Secures Japan's First Global Approval for Hibsago (Bepirovirsen) as Functional Cure for Chronic Hepatitis B
2 outlets - including Investing and Kalkinemedia - are covering this story. On 24th August 2026, GSK plc (LSE/NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B in adult patients meeti…
Covered by 2 outlets
All coverage · 2 articles
Investing.com UK
·3h ago
GSK’s Hibsago wins first global approval in Japan for hepatitis B
Kalkine Media UK
·3h ago
GSK Secures Japan's First Global Approval for Hibsago (Bepirovirsen) as Functional Cure for Chronic Hepatitis B
On 24th August 2026, GSK plc (LSE/NYSE: GSK) announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B in adult patients meeti…